Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

The danger control concept in kidney disease: mesangial cells.

Migliorini A, Ebid R, Scherbaum CR, Anders HJ.

J Nephrol. 2013 May-Jun;26(3):437-49. doi: 10.5301/jn.5000247. Epub 2013 Mar 5. Review.

PMID:
23475470
2.
3.

Mesangial homeostasis and pathobiology: their role in health and disease.

Herrera GA, Turbat-Herrera EA, Teng J.

Contrib Nephrol. 2011;169:6-22. doi: 10.1159/000314774. Epub 2011 Jan 20.

PMID:
21252508
4.

Mesangial cells and their adhesive properties.

Pröls F, Hartner A, Schöcklmann HO, Sterzel RB.

Exp Nephrol. 1999 Mar-Apr;7(2):137-46. Review.

PMID:
10213867
5.

Mesangial cells and glomerular inflammation: from the pathogenesis to novel therapeutic approaches.

Gómez-Guerrero C, Hernández-Vargas P, López-Franco O, Ortiz-Muñoz G, Egido J.

Curr Drug Targets Inflamm Allergy. 2005 Jun;4(3):341-51. Review.

PMID:
16101544
6.

Role of coagulation in glomerular injury.

Kanfer A.

Toxicol Lett. 1989 Mar;46(1-3):83-92. Review.

PMID:
2650038
7.

Podocyte damage damages podocytes: autonomous vicious cycle that drives local spread of glomerular sclerosis.

Ichikawa I, Ma J, Motojima M, Matsusaka T.

Curr Opin Nephrol Hypertens. 2005 May;14(3):205-10. Review.

PMID:
15821411
8.

[The humoral and cellular factors of glomerular damage].

Camussi G, Montrucchio G.

Ann Ital Med Int. 1992 Oct-Dec;7(4):226-33. Review. Italian.

PMID:
1298333
9.

The role of mesangial homeostasis in glomerular injury progression: hope for mesangial sclerosis reversal.

Picken MM.

Kidney Int. 2009 Mar;75(6):574-6. doi: 10.1038/ki.2008.651. Review.

10.

Vascular endothelial growth factor enhances glomerular capillary repair and accelerates resolution of experimentally induced glomerulonephritis.

Masuda Y, Shimizu A, Mori T, Ishiwata T, Kitamura H, Ohashi R, Ishizaki M, Asano G, Sugisaki Y, Yamanaka N.

Am J Pathol. 2001 Aug;159(2):599-608.

11.

Danger control programs cause tissue injury and remodeling.

Hagemann JH, Haegele H, Müller S, Anders HJ.

Int J Mol Sci. 2013 May 28;14(6):11319-46. doi: 10.3390/ijms140611319. Review.

12.

Pathogenesis of glomerular damage in glomerulonephritis.

Couser WG.

Nephrol Dial Transplant. 1998;13 Suppl 1:10-5. Review.

PMID:
9507491
13.

Mechanisms of mesangial injury in glomerular diseases.

Daha MR.

J Nephrol. 2000 Nov-Dec;13 Suppl 3:S89-95. Review.

PMID:
11132039
14.

Healing the damaged mesangium in nodular glomerulosclerosis using mesenchymal stem cells (MSCs): Expectations and challenges.

Herrera GA, Zeng C, Turbat-Herrera EA, Teng J.

Ultrastruct Pathol. 2016;40(2):61-70. doi: 10.3109/01913123.2016.1145776. Review.

PMID:
27031175
15.

The pathogenetic role of the coagulation process in glomerular diseases of immunologic origin.

Vassalli P, McCluskey RT.

Adv Nephrol Necker Hosp. 1971;1:47-63. Review.

PMID:
4143241
16.

[Structure and function of mesangium].

Yamamoto T.

Nihon Rinsho. 2006 Feb;64 Suppl 2:65-9. Review. Japanese. No abstract available.

PMID:
16523861
17.

The progression of renal disease.

Klahr S, Schreiner G, Ichikawa I.

N Engl J Med. 1988 Jun 23;318(25):1657-66. Review.

PMID:
3287163
18.

Beta1-integrins and glomerular injury.

Kagami S, Kondo S.

J Med Invest. 2004 Feb;51(1-2):1-13. Review.

19.

Glomerular podocytes and adhesive interaction with glomerular basement membrane.

Mundel P, Shankland SJ.

Exp Nephrol. 1999 Mar-Apr;7(2):160-6. Review.

PMID:
10213869
20.

The role of platelet-activating factor (PAF) in experimental glomerular injury.

Ortiz A, Gomez-Chiarri M, Lerma JL, Gonzalez E, Egido J.

Lipids. 1991 Dec;26(12):1310-5. Review.

PMID:
1819722

Supplemental Content

Support Center